The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
Open accessAbstract
Introduction: Tamoxifen therapy reduces the risk of recurrence and prolongs the survival of oestrogen-receptor-positive patients with breast cancer. Even if most patients benefit from tamoxifen, many breast tumours either fail to respond or become resistant. Because tamoxifen is extensively metabolised by polymorphic enzymes, one proposed mechanism underlying the resistance is altered metabolism. In the present study we investigated the prognostic and/or predictive value of functional polymorphisms in cytochrome P450 3A5 CYP3A5 (*3), CYP2D6 (*4), sulphotransferase 1A1 (SULT1A1; *2) and UDP-glucuronosyltransferase 2B15 (UGT2B15; *2) in tamoxifen-treated patients with breast cancer. Methods: In all, 677 tamoxifen-treated postmenopausal patients with breast cancer, of whom 238 were randomised to either 2 or 5 years of tamoxifen, were genotyped by using PCR with restriction fragment length polymorphism or PCR with denaturing high-performance liquid chromatography. Results: The prognostic evaluation performed in the total population revealed a significantly better disease-free survival in patients homozygous for CYP2D6*4. For CYP3A5, SULT1A1 and UGT2B15 no prognostic significance was observed. In the randomised group we found that for CYP3A5, homozygous carriers of the *3 allele tended to have an increased risk of recurrence when treated for 2 years with tamoxifen, although this was not statistically significant (hazard ratio (HR) = 2.84, 95% confidence interval (CI) = 0.68 to 11.99, P = 0.15). In the group randomised to 5 years' tamoxifen the survival pattern shifted towards a significantly improved recurrence-free survival (RFS) among CYP3A5*3-homozygous patients (HR = 0.20, 95% CI = 0.07 to 0.55, P = 0.002). No reliable differences could be seen between treatment duration and the genotypes of CYP2D6, SULT1A1 or UGT2B15. The significantly improved RFS with prolonged tamoxifen treatment in CYP3A5*3 homozygotes was also seen in a multivariate Cox model (HR = 0.13, CI = 0.02 to 0.86, P = 0.03), whereas no differences could be seen for CYP2D6, SULT1A1 and UGT2B15. Conclusion: The metabolism of tamoxifen is complex and the mechanisms responsible for the resistance are unlikely to be explained by a single polymorphism; instead it is a combination of several mechanisms. However, the present data suggest that genetic variation in CYP3A5 may predict response to tamoxifen therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,162
Genetic contribution to variable human CYP3A-mediated metabolism
Lamba, J. K., Lin, Y. S., Schuetz, E. G., & Thummel, K. E. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00066-2 · Cited by 990
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
Howell, A. (1998) · PubMed · Cited by 901
Stearns, V. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg108 · Cited by 850
Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Flockhart, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3266 · Cited by 791
The genetic determinants of the CYP3A5 polymorphism
Hustert, E., Haberl, M., Burk, O., Wolbold, R., He, Y.-Q., Klein, K., Nuessler, A. C., Neuhaus, P., Klattig, J., Eiselt, R., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200112000-00005 · Cited by 673
Johnson, M. D., Zuo, H., Lee, K.-H., Trebley, J. P., Rae, J. M., Weatherman, R. V., Desta, Z., Flockhart, D. A., & Skaar, T. C. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000025406.31193.e8 · Cited by 456
Coezy, E. D., Borgna, J., & Rochefort, H. (1982) · PubMed · Cited by 394
Interindividual Variability and Tissue-Specificity in the Expression of Cytochrome P450 3A mRNA
Koch, I., Weil, R., Wolbold, R., Brockmöller, J., Hustert, E., Burk, O., Nuessler, A., Neuhaus, P., Eichelbaum, M., Zanger, U., et al. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.10.1108 · Cited by 314
Lim, Y. C., Desta, Z., Flockhart, D. A., & Skaar, T. C. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0926-7 · Cited by 309
Nowell, S. A., Ahn, J., Rae, J. M., Scheys, J. O., Trovato, A., Sweeney, C., MacLeod, S. L., Kadlubar, F. F., & Ambrosone, C. B. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-7751-x · Cited by 306
Raftogianis, R. B., Wood, T. C., Otterness, D. M., Van Loon, J. A., & Weinshilboum, R. M. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7466 · Cited by 305
Katzenellenbogen, B. S., Norman, M. J., Eckert, R. L., Peltz, S. W., & Mangel, W. F. (1984) · PubMed · Cited by 276
Westlind-Johnsson, A., Malmebo, S., Johansson, A., Otter, C., Andersson, T. B., Johansson, I., Edwards, R. J., Boobis, A. R., & Ingelman-Sundberg, M. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.6.755 · Cited by 258
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
Wegman, P., Vainikka, L., Stål, O., Nordenskjöld, B., Skoog, L., Rutqvist, L.-E., & Wingren, S. (2005) · Breast Cancer Research · doi:10.1186/bcr993 · Cited by 243
Self-citationCrewe, H. K., Ellis, S. W., Lennard, M. S., & Tucker, G. T. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(96)00650-8 · Cited by 223
Levesque, E., Beaulieu, M., GreeN, M. D., Tephly, T. R., Belanger, A., & Hum, D. W. (1997) · Pharmacogenetics · doi:10.1097/00008571-199708000-00007 · Cited by 218
Kisanga, E. R., Gjerde, J., Guerrieri-Gonzaga, A., Pigatto, F., Pesci-Feltri, A., Robertson, C., Serrano, D., Pelosi, G., Decensi, A., & Lien, E. A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0538 · Cited by 197
CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.
Dehal, S. S., & Kupfer, D. (1997) · PubMed · Cited by 187
Jacolot, F., Simon, I., Dreano, Y., Beaune, P., Riche, C., & Berthou, F. (1991) · Biochemical Pharmacology · doi:10.1016/0006-2952(91)90131-n · Cited by 179
Nowell, S. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.21.1635 · Cited by 160
Pharmacokinetics of Midazolam and 1′-Hydroxymidazolam in Chinese with Different CYP3A5 Genotypes
Shih, P.-S., & Huang, J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1491 · Cited by 138
Coughtrie, M. W. H., Gilissen, R., Benedicte, S. H. E. K., Strange, R. C., Fryer, A. A., Jones, P. W., & Bamber, D. E. (1998) · Biochemical Journal · doi:10.1042/bj3370045 · Cited by 128
Nishiyama, T., Ogura, K., Nakano, H., Ohnuma, T., Kaku, T., Hiratsuka, A., Muro, K., & Watabe, T. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00994-2 · Cited by 109
Fabian, C. J., Tilzer, L. L., & Sternson, L. A. (1981) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2510020407 · Cited by 102
Murphy, C. S., Langan-Fahey, S. M., McCague, R., & Jordan, V. C. (1990) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09527-6 · Cited by 88
Cancer treatment and pharmacogenetics of cytochrome P450 enzymes
van Schaik, R. H. N. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-4019-1 · Cited by 82
Tucker, A. N., Tkaczuk, K. A., Lewis, L. M., Tomic, D., Lim, C. K., & Flaws, J. A. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.08.027 · Cited by 62
Lack of Attenuation in the Antitumor Effect of Tamoxifen by Chronic CYP Isoform Inhibition
Lehmann, D. F., Nelsen, J. L., Ramanath, V. S., Newman, N. B., Duggan, D. B., & Smith, A. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004266618 · Cited by 29
Cited by
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part I
Zhou, S.-F. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318030-000000000-00000 · Cited by 756
Schroth, W. (2009) · JAMA · doi:10.1001/jama.2009.1420 · Cited by 531
Schroth, W., Antoniadou, L., Fritz, P., Schwab, M., Muerdter, T., Zanger, U. M., Simon, W., Eichelbaum, M., & Brauch, H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2705 · Cited by 467
The UDP-Glycosyltransferase (UGT) Superfamily: New Members, New Functions, and Novel Paradigms
Meech, R., Hu, D. G., McKinnon, R. A., Mubarokah, S. N., Haines, A. Z., Nair, P. C., Rowland, A., & Mackenzie, P. I. (2019) · Physiological Reviews · doi:10.1152/physrev.00058.2017 · Cited by 368
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part II
Zhou, S.-F. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318070-000000000-00000 · Cited by 330
Metadata
- Authors
- Wegman, P., Elingarami, S., Carstensen, J., Stål, O., Nordenskjöld, B., & Wingren, S.
- Venue
- Breast Cancer Research
- Published
- 2007-01-23
- Volume
- 9
- Issue
- 1
- Pages
- R7-R7
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W1631027698
- Cited by
- 288
- References
- 31
- FWCI
- 31.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.